Business Context and Reporting Period
This Form 8-K is a current report filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata, but identified as OncoGenex in the filing text) on March 10, 2011. The filing announces the company's financial results for the fourth quarter and full year ended December 31, 2010. The report references a press release (Exhibit 99.1) containing the detailed results.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1), which is not included in the input text. Consequently, no specific financial metrics can be extracted from this document alone.
Material Changes
The filing does not provide specific data to compare current period performance against prior periods. It serves solely as a notification that the results for Q4 and full-year 2010 have been issued.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing the attached Exhibit 99.1 (Press Release), as they are absent from the 8-K text.
- Confirm the company's current legal name and ticker status, noting the discrepancy between the metadata ("ACHIEVE LIFE SCIENCES, INC.") and the filing header ("ONCOGENEX PHARMACEUTICALS, INC.").
- Review the press release for any updates on clinical trial progress or product development, which are typical material events for this sector but not detailed in this summary.